drugset / Trial / NCT00006243
Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma
RandomizedParallel-groupOpen-labelTreatment
Summary
This randomized pilot clinical trial studies vaccine therapy and sargramostim in treating patients with stage IV malignant melanoma. Vaccines made from melanoma peptides or antigens may help the body build an effective immune response to kill tumor cells. Colony-stimulating factors, such as sargramostim, increase the number of white blood cells and platelets found in bone marrow or peripheral blood. Giving vaccine therapy together with sargramostim may be an effective treatment for malignant melanoma
Timeline
- Start
- 2000-10
- Primary completion
- 2006-05
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MART-1:27-35 peptide vaccine | Vaccine | — | Subcutaneous |
| Subject | gp100 antigen | Peptide | — | Subcutaneous |
| Subject | sargramostim | Protein / enzyme biologic | — | Subcutaneous |
| Subject | tyrosinase peptide | Peptide | — | Subcutaneous |
| Background | incomplete Freund's adjuvant | Other / unclassified | — | Subcutaneous |